Metropolis Healthcare Ltd

Metropolis Healthcare Limited announced that its Nomination and Remuneration Committee approved the allotment of 66,312 equity shares at an exercise price of INR 2 each, aggregating to INR 1,32,624, against vested and exercised Restrictive Stock Units under the Metropolis -Restrictive Stock Unit Plan, 2020. The newly issued shares, with a par value of INR 2, have a distinctive number range of 20,73,87,569 to 20,74,53,880, and will rank pari-passu with existing shares, with 50% of the shares subject to a one-year lock-in period expiring on September 8, 2027.

Metropolis Healthcare Limited announced that its subsidiary, Metropolis Quality Solutions Private Limited, has entered into a Share Subscription Agreement with Medsource Ozone Biomedicals Private Limited and Dr. Puneet Kumar Nigam, and a Shareholder’s Agreement with Medsource, Metropolis Healthcare Limited, and Dr. Puneet Kumar Nigam, to consolidate and streamline the External Quality Assessment Services Business. Medsource will invest approximately Rs 1.10 crore and Dr. Puneet Kumar Nigam will invest Rs 16 lakh in Metropolis Quality Solutions Private Limited, resulting in a shareholding structure of 54.90% for Metropolis Healthcare Limited, 30.60% for Medsource, and 14.50% for Dr. Puneet Kumar Nigam upon completion of the transaction and conversion of Optionally Convertible Redeemable Preference Shares.

Metropolis Healthcare Limited informed the BSE Limited and National Stock Exchange of India that its wholly owned subsidiary, Metropolis Quality Solutions Private Limited (MQSPL), has approved the offer and issuance of 10,000 Optionally Convertible Redeemable Preference Shares (OCRPS) with a face value of Rs 10 each, aggregating to Rs 1,00,000, to Dr. Puneet Kumar Nigam, a former Chief Quality Officer of the company, with the conversion into equity shares expected to occur in tranches over up to 6 years; upon conversion, MQSPL will cease to be a wholly owned subsidiary but will remain a subsidiary of Metropolis Healthcare Limited.

Metropolis Healthcare Ltd share price slipped 1.37% to Rs 588.2. The Company's net profit expanded by 11.62% to Rs 56.88 crore, while revenue from operations slightly gained 6.01% to Rs 450.22 crore in Q2FY26 over Q1FY26. The market capitalization of Healthcare Service Provider industry group stocks on BSE stood at Rs 70065.21 crore, easing 8.31%. It has inched up 2.76% over last one week and rallied by 18.26% in last one month while the market capitalization of Metropolis Healthcare Ltd has improved by 0.38% and 16.20% in the same period respectively. Profit before tax (PBT) of Metropolis Healthcare Ltd stood at Rs 77.71 crore in Q2 FY26, rallying 26.91% year-on-year, and heading higher 11.40% quarter-on-quarter. EBITDA came in at Rs 106 crore, jumping 29.00% YoY and rising 6.24% sequentially. Total expenses saw a slight increase of 4.55% to Rs 371.43 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 87.1 crore, increasing 10.98% YoY, while employee benefits expense was at Rs 106.98 crore, witnessing a strong rise of 12.06% YoY. For the TTM ended FY26, revenue from operations surged 23.64% to Rs 1645.85 crore, while net profit saw a strong growth of 31.39% to Rs 191.18 crore, compared to previous TTM. EBITDA surged by 31192% to Rs 375.26 crore, and PBT soared 35.80% to Rs 259.18 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 350.7 crore in FY26, as against Rs 262.75 crore in FY25. Metropolis Healthcare Ltd rallied 17.12% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 2.94% during the same period.

Metropolis Healthcare Limited reported revenue of Rs 450 crore for the quarter ended June 30, 2026, a 17% increase year-over-year, alongside a 27% rise in earnings before interest, taxes, depreciation, and amortization (EBITDA) to Rs 113 crore, according to a press release. The Mumbai-based diagnostics company, led by Ameera Shah, also saw patient volume grow 10% year-over-year and test volume increase 11% year-over-year, with TruHealth revenue growing 22% to Rs 81 crore and Specialty revenue increasing 17% to Rs 178 crore.

Metropolis Healthcare Limited informed the BSE Limited and National Stock Exchange of India that its Nomination and Remuneration Committee approved the allotment of 18,700 equity shares at an exercise price of Rs 2 each, aggregating to Rs 37,400, under the Metropolis -Restrictive Stock Unit Plan, 2020, and the grant of 1,380 units under the Metropolis – Restrictive Stock Units Plan, 2025, and 20,500 options under the Metropolis – Employees Stock Options Plan, 2025.

Metropolis Healthcare will hold a meeting of the Board of Directors of the Company on 4 August 2026.

Metropolis Healthcare announced that the 26th Annual General Meeting(AGM) of the company will be held on 18 August 2026.

Metropolis Healthcare has allotted 36,900 equity shares under he Metropolis-Restrictive Stock Unit Plan, 2020 on 09 July 2026.

The company said the TruHealth Wellness and Specialty segments are the fastest growing segments for the quarter. In B2C business registered healthy volume growth, driven by increased throughput from the expanded center network. B2B volumes also grew, supported by higher wallet share and new customer acquisition, backed by improved service quality and delivery levels. The company said EBITDA margins improved on a YoY basis in line with guidance. On quarter-on-quarter basis, margins remained largely stable. During the Q4 earnings call, promoter Ameer Shah said the company has guided for a sustainable group EBITDA margin of 27%'28% over the next three years. Metropolis Healthcare is India's second-largest pathology laboratory chain, offering diagnostic testing and related services across a nationwide network, with a strong presence in specialised and preventive healthcare diagnostics. The company's consolidated net profit rose 74.67% to Rs 50.90 crore on 22.99% increase in revenue from operations to Rs 424.68 crore in Q4 FY26 over Q4 FY25.Powered by Capital Market - Live